This study is testing if a medication called dalbavancin, given with a fluoroquinolone (like ciprofloxacin or levofloxacin), can help prevent serious bacterial bloodstream infections in children and adolescents with acute myeloid leukemia (AML) or relapsed acute lymphoblastic leukemia (ALL). These patients are at high risk for infection because their chemotherapy causes a severe drop in white blood cells (severe neutropenia). The study aims to see how well dalbavancin prevents these infections and how well patients tolerate it. You might be able to join if you are 25 years old or younger, have AML or relapsed ALL, and are receiving treatment at St. Jude that is expected to cause prolonged severe neutropenia. The study is currently unclear on its status and plans to enroll 29 participants.

Study design

This is a single-arm, open-label study, meaning all participants receive the same treatment and both you and your doctors will know what you are receiving. It plans to enroll 29 participants.

What's involved

You would receive up to three doses of dalbavancin every 28 days, along with a fluoroquinolone, for up to 12 weeks. Baseline samples, including stool, will be collected, and blood samples will be taken to see how the drug moves through your body.

Compensation

Not stated in the trial record.

Follow-up

The primary goal is to measure bacterial bloodstream infections at Day 56. Participants will receive treatment for up to 12 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.